Loading...
•
Jun 28, 2025
Bioventus Q2 2025 Earnings Report
Bioventus reported its second quarter financial results, with a slight revenue decline but significant improvements in net income and non-GAAP EPS.
Key Takeaways
Bioventus delivered a strong second quarter, with reported revenue of $147.7 million, a 2.4% decline year-over-year due to a prior-year divestiture. However, organic revenue grew by 6.2%, driven by double-digit organic growth in Surgical Solutions and Restorative Therapies. The company significantly improved its net income to $7.5 million from a loss of $25.7 million in the prior year, and non-GAAP EPS increased by 31% to $0.21. Cash from operations also saw a substantial increase of 71% to $25.9 million.
Reported revenue for Q2 2025 was $147.7 million, a 2.4% decrease year-over-year, primarily due to the divestiture of the Advanced Rehabilitation Business.
Organic revenue grew by 6.2%, with strong performance in Surgical Solutions and Restorative Therapies.
Net income attributable to Bioventus Inc. improved significantly to $7.5 million, compared to a net loss of $25.7 million in the prior-year period.
Non-GAAP diluted earnings per share increased by 31% to $0.21, driven by lower interest expense and equity-based compensation.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bioventus reiterated its full-year 2025 financial guidance, expecting net sales between $560 million and $570 million, Adjusted EBITDA between $112 million and $116 million, and Non-GAAP EPS between $0.64 and $0.68.
Positive Outlook
- Reiterated net sales guidance of $560 million to $570 million for full year 2025.
- Expected organic growth of approximately 6.1% to 8.0% for full year 2025, even with the impact of the Advanced Rehabilitation Business divestiture.
- Reiterated Adjusted EBITDA guidance of $112 million to $116 million for full year 2025.
- Anticipated 100 basis points in Adjusted EBITDA Margin growth compared to 2024.
- Reiterated Non-GAAP EPS guidance of $0.64 to $0.68, reflecting an increase of 30.6% to 38.8%.
Challenges Ahead
- Guidance assumes successful offset of $5 million related to foreign exchange expense incurred in the first half of the year.
- Guidance assumes successful offset of the full year expected impact of current tariffs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...